Abstract
Despite significant advancements in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) since the advent of crizotinib, the development of acquired resistance and poor CNS efficacy have necessitated the search for novel and more robust therapies. Ensartinib (X-396) is a novel second-generation ALK-tyrosine kinase inhibitor (TKI) that holds much clinical promise. Preclinical data have demonstrated increased potency of the drug as compared with crizotinib and other second-generation ALK-TKI therapies such as alectinib and ceritinib. This review highlights the first- A nd second-generation ALK inhibitors approved for the treatment of ALK-positive NSCLC and discusses the clinical trial protocol for the eXalt3 trial (NCT02767804) comparing the efficacy and safety of ensartinib to crizotinib in patients diagnosed with ALK-positive NSCLC who are naive to prior ALK-TKI treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 1781-1787 |
Number of pages | 7 |
Journal | Future Oncology |
Volume | 14 |
Issue number | 18 |
DOIs | |
State | Published - Aug 2018 |
Externally published | Yes |
Keywords
- biomarkers/oncogenes/molecular oncology
- clinical trials
- lung
ASJC Scopus subject areas
- Oncology
- Cancer Research